MedTrace Logo

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

NCT04068831 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-12-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.

Conditions

  • Metastatic Renal Cell Carcinoma
  • Fumarate Hydratase Deficient Renal Cell Carcinoma
  • Succinate Dehydrogenase Deficient Renal Cell Carcinoma

Interventions

DRUG

Talazoparib

1 mg talazoparib daily

DRUG

Avelumab

800 mg avelumab every 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Ritesh Kotecha, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-22
Primary Completion
2023-12-06
Completion
2023-12-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04068831 on ClinicalTrials.gov